Efficacy and safety of 2-4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta-analysis
{{output}}
Brexpiprazole 2-4 mg daily is a novel dopamine D2 partial agonist approved for schizophrenia and improves effectiveness and tolerance by balancing D2, 5-HT1A, and 5-HT2A effects. This review assesses current evidence on its efficacy and safety within this dose... ...
